ALDH1A3 and neoplasm: To validate that the compounds discovered could block ALDH1A3 activity in a relevant disease model, we sought to test a syngeneic tumor model whose in vivo tumor growth was shown to be dependent on ALDH1A3 production of atRA and resultant immune suppression.24